For Drug Maker, M&A Does Work of R&D

J. Michael Pearson, chief executive of Valeant Pharmaceuticals, made 13 takeover bids last year. He succeeded in 11 of them, spending about $2.78 billion to beef up the Montreal pharmaceutical company’s dermatology, neurology, branded generics and OTC products businesses.
The Wall Street Journal